The patent grant is a positive catalyst that de-risks the IP landscape ahead of Phase 3 initiation. Monitor for partnership announcements or financing updates as the company approaches Phase 3 startup.
Price Chart
Executive Summary
Alterity Therapeutics announced the USPTO granted a new composition-of-matter patent for ATH434, its lead clinical asset for Multiple System Atrophy (MSA). The patent extends protection to at least 2045, strengthening the drug's IP position as the company prepares to initiate Phase 3 trials by year-end 2026.
Key Facts
- USPTO granted a new composition-of-matter patent for ATH434, covering the crystalline mesylate salt form and methods of treating neurological conditions.
- Patent extends protection for ATH434 to at least 2045, significantly extending the commercial life if approved.
- Alterity is preparing to initiate Phase 3 trial activities in MSA by year-end 2026.
- ATH434 has Fast Track Designation from the FDA and Orphan Drug Designation from the FDA and European Commission for MSA.
- The patent is expected to be listed in the FDA's Orange Book upon regulatory approval of ATH434.
Financial Impact
No financial figures provided in the filing. The patent extends the potential revenue-generating life of ATH434 to at least 2045, but the asset is pre-commercial and pre-revenue.
Risk Factors
- ATH434 is still in clinical development and requires successful Phase 3 trials and regulatory approval before commercialization.
- The company is a development-stage enterprise with no approved products or revenue, creating financing risk for the Phase 3 program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-027454 |
| Document: athe20260812_6k.htm | 0001437749-26-027454 |
| Document: 0001437749-26-027454-index-headers.html | 0001437749-26-027454 |
| Document: 0001437749-26-027454-index.html | 0001437749-26-027454 |
| Document: 0001437749-26-027454.txt | 0001437749-26-027454 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers